How Biomarker Testing Shapes Lung Cancer Treatment Plans

When you’re first told you have lung cancer, it can feel like treatment is one-size-fits-all, but it isn’t, and biomarker testing is a big reason why. These tests look for specific changes in your cancer’s DNA, RNA, or proteins that can open the door to targeted drugs and tailored immunotherapy. Understanding what’s being tested, when to ask for it, and how results guide your options can change your entire treatment path…

What Are Lung Cancer Biomarkers and Why Do They Matter?

According to Dr.James Wilson, a lung & skin cancer specialist working in London, when doctors refer to lung cancer “biomarkers,” they mean specific genes, proteins, or other molecules found in the tumor tissue or sometimes in the blood that can help guide diagnosis and treatment decisions. Common biomarkers in non–small cell lung cancer include EGFR, KRAS G12C, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK, HER2, and PD‑L1.

Testing looks for changes in DNA, RNA, or proteins that may be driving the growth of the cancer. Most of these changes are somatic, meaning they occur only in the tumor cells and aren't inherited.

If testing identifies an “actionable” biomarker, one for which there's an available targeted therapy, you may be eligible for specific FDA‑approved drugs. These targeted treatments are often more effective and may have different side‑effect profiles compared with non‑targeted options such as standard chemotherapy.

Where Biomarker Testing Fits in Your Lung Cancer Care

From the time non–small cell lung cancer is diagnosed, biomarker testing plays a central role in planning treatment. Your care team typically uses next‑generation sequencing on tumor tissue, or in some cases a liquid biopsy, to identify specific DNA and RNA changes such as EGFR, ALK, ROS1, BRAF V600E, MET, RET, NTRK, KRAS, and HER2.

In addition, testing for the PD‑L1 protein helps estimate the likelihood of response to immunotherapy. These results guide whether initial treatment is more likely to involve a targeted oral therapy, immunotherapy, chemotherapy, or a combination. Biomarker testing may be repeated or expanded over time, since the molecular characteristics of the cancer can change and new targeted treatment options may become available.

When to Get Biomarker Testing and What to Expect

Now that you know how biomarker results can guide your lung cancer treatment plan, it's useful to understand when testing is done and what the process involves. If possible, talk with your care team before the initial biopsy so they can collect enough tissue for comprehensive next‑generation sequencing (NGS) and PD‑L1 testing.

Tumor-based NGS results typically take about 1–2 weeks. If the tissue sample is limited, you can ask about using any remaining stored tissue, repeating the biopsy, or using a blood-based (liquid) biopsy as an alternative. Ensure that testing includes important targets such as EGFR, ALK, ROS1, BRAF V600E, MET, RET, NTRK, KRAS, and HER2, in line with current clinical guidelines.

Before testing, review your insurance coverage and any available financial assistance with your care team or a financial counselor. If coverage for comprehensive testing is denied, you can ask about the appeals process or alternative options to obtain the recommended tests.

Tissue vs. Liquid Biopsy: How Biomarker Testing Is Done

Although both tests look for the same cancer‑related changes, tissue and liquid biopsies obtain this information in different ways.

In a tissue biopsy, a sample of the tumor is removed so the laboratory can analyze DNA, RNA, and proteins, including PD‑L1 expression. Tumor tissue next‑generation sequencing (NGS) is generally recommended at diagnosis because it more reliably detects certain alterations, such as gene fusions and complex or mixed mutations.

A liquid biopsy uses a blood sample to assess circulating tumor DNA. It's less invasive and typically provides results more quickly, but it may miss some mutations, particularly gene fusions or alterations present at low levels.

When tissue from the initial biopsy is limited, the care team may consider options such as combining remaining tissue samples, performing a repeat tissue biopsy, or using blood‑based testing, depending on the available laboratory methods, clinical context, and insurance coverage.

Key Lung Cancer Biomarkers That Guide Targeted Treatment

A number of specific biomarkers in non‑small cell lung cancer (NSCLC) now guide the selection of targeted therapies and immunotherapies. Common “driver” alterations with approved targeted drugs include EGFR mutations (particularly exon 19 deletions and L858R), as well as ALK and ROS1 rearrangements.

Other relevant alterations include BRAF V600E, MET exon 14 skipping or amplification, RET and NTRK fusions, HER2 (ERBB2) alterations, KRAS G12C, and emerging NRG1 fusions. KRAS mutations are found in approximately 30% of NSCLC cases, while EGFR mutations occur in about 20–25%, with some variation by population. PD‑L1 expression levels are used to guide the use and intensity of immunotherapy.

Additional co‑mutations, such as TP53, STK11, or KEAP1, may influence prognosis and response to certain treatments, and are increasingly considered when designing individualized treatment plans.

How Your Biomarker Results Shape Targeted and Immune Therapy

Understanding your lung cancer biomarkers allows your care team to move from a general treatment strategy to a personalized plan, particularly for targeted therapies and immunotherapy.

If testing identifies an actionable driver alteration, such as EGFR, ALK, ROS1, BRAF V600E, MET exon 14 skipping, RET or NTRK fusions, or KRAS G12C, clinicians often recommend an FDA‑approved targeted pill or infusion. These drugs are designed to block the specific alteration that's helping the cancer grow and, in many cases, can control the disease for longer than chemotherapy alone.

Your PD‑L1 tumor proportion score is then used to help guide immunotherapy choices. A high PD‑L1 level may support the use of immunotherapy on its own, while low or absent PD‑L1 expression more often leads to a combination of chemotherapy and immunotherapy.

Treatment decisions also take into account other clinical factors, such as overall health, symptoms, and previous treatments.

If No Targetable Biomarker Is Found: Options, Trials, and Retesting

Even when biomarker testing doesn't identify a targetable mutation, the results remain important for planning treatment.

In this situation, standard treatment often involves chemotherapy, sometimes combined with immunotherapy based on your PD‑L1 level, and may include surgery or radiation when appropriate for the stage and location of the cancer.

It is also reasonable to ask about clinical trials. These studies may provide access to new targeted therapies or immunotherapy combinations that aren't yet widely available in routine practice.

If the cancer progresses, repeat testing with a new tissue biopsy or a liquid biopsy may be considered.

Over time, new genetic changes, such as MET, RET, or NTRK fusions, or mutations associated with treatment resistance, can emerge.

Identifying these changes may create additional treatment options, even if earlier testing didn't show a targetable biomarker.

Biomarker Testing Costs, Access, and Questions to Ask Your Care Team

Often, the more difficult aspects of biomarker testing are cost, timing, and logistics rather than the science itself.

Most comprehensive next‑generation sequencing (NGS) panels performed on tumor tissue (sometimes including DNA, RNA, and protein) return results in about 1–2 weeks. These panels are widely recommended for people with non‑small cell lung cancer, as they can identify multiple actionable biomarkers from a single test.

It is important to ask your care team what your insurance plan covers, whether prior authorization is required, and if there are assistance programs from the testing laboratory or manufacturer that can help reduce or eliminate out‑of‑pocket costs.

If the amount of tumor tissue is limited, you can ask about options such as using leftover tissue from a prior biopsy, repeating a biopsy, or using a liquid biopsy (a blood‑based test), and discuss the advantages and limitations of each approach.

You may also want to clarify which specific genes and biomarkers will be included in the panel, who'll review and explain the results with you, whether there's a plan for retesting in the future as new therapies become available, and what steps can be taken to appeal if your insurance denies coverage for testing.

Lung Cancer Biomarker Testing: Checklists, Experts, and Trusted Resources

While cost, timing, and logistics can be challenging, biomarker testing can be made more manageable by following structured steps and involving appropriate specialists.

At the time of diagnosis of non–small cell lung cancer, ask whether comprehensive next‑generation sequencing (NGS) of both DNA and RNA will be performed to identify targetable alterations.

Before the biopsy, confirm that the planned procedure is likely to obtain enough tissue to allow for NGS, PD‑L1 testing, and fusion or exon‑skipping analyses.

If tissue is limited, ask about options such as using remaining tissue blocks, repeating the biopsy, or adding a liquid biopsy (blood‑based test).

Review the results with your oncologist and, when available, consider discussion at a molecular tumor board, where a multidisciplinary team reviews complex cases.

It is also useful to clarify insurance coverage, patient assistance or lab support programs, and anticipated out‑of‑pocket costs in advance to reduce unexpected financial burdens.

Conclusion

Biomarker testing gives you a clearer map for your lung cancer treatment, so you’re not relying on guesswork. By knowing your tumor’s specific changes, you and your care team can choose targeted drugs, immunotherapy, or combinations that are more likely to help. Ask about comprehensive testing early, revisit it if your cancer changes, and use your results to explore all options, including clinical trials, so you can make informed, personalized decisions at every step.